StockNews.com Upgrades Repligen (NASDAQ:RGEN) to "Hold"

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN - Free Report) from a sell rating to a hold rating in a research report released on Friday.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Royal Bank of Canada lifted their price target on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Finally, Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $178.64.

Remove Ads

Repligen Trading Up 6.9 %

Shares of Repligen stock traded up $7.48 during trading on Friday, reaching $116.37. 493,475 shares of the stock were exchanged, compared to its average volume of 694,073. The firm has a market cap of $6.53 billion, a price-to-earnings ratio of -230.77, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The stock's fifty day moving average is $146.48 and its 200 day moving average is $146.91. Repligen has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities research analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other news, Director Margaret Pax acquired 250 shares of the company's stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.20% of the company's stock.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently modified their holdings of RGEN. Signaturefd LLC boosted its stake in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen in the fourth quarter worth about $29,000. Raiffeisen Bank International AG bought a new position in shares of Repligen in the 4th quarter valued at about $29,000. Resources Management Corp CT ADV acquired a new stake in Repligen in the 3rd quarter valued at $37,000. Finally, Quarry LP lifted its position in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after buying an additional 239 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.